Brief: ABVC Biopharma Announces Enrollment Progress For ADHD Phase II Part 2 Clinical Study
01/06/2022 13:31
June 1 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA ANNOUNCES ENROLLMENT PROGRESS FOR ADHD
PHASE II
PART 2 CLINICAL STUDY
* ABVC BIOPHARMA INC- SINCE FIRST SUBJECT BEGAN TREATMENT ON
MAY
10, 2022, 13 ADDITIONAL SUBJECTS HAVE BEEN ENROLLED IN STUDY
Source text for Eikon: ID:nGNXbdXnnj
Further company coverage: ABVC.O
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma Says Biokey Share Distribution Rescheduled For August 21
NASDAQ RESUMED AT 09:05 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:43 PM
Brief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon